AB 1103: Faster Pathways for Psychedelics and Controlled-Substance Research in California

After a few failed attempts, could psychedelics be moving closer to a legal regulated market in California? Recently, Governor Newsom signed AB 1103 that would authorize the Research Advisory Panel of California (“RAPC”) to expedite review of research of psychedelics to treat conditions such as depression and PTSD until January 1,2028. RAPC is responsible for reviewing research studies using Schedule I and Schedule II controlled substances.

Key Highlights:

• • Expedited review: Until January 1, 2028, eligible research projects can receive RAPC approval through an accelerated process rather than waiting for a full panel meeting.

• • Eligibility: Projects must already have federal or institutional approvals (FDA IND, DEA registration, and/or IRB clearance).

• • Delegated review: The RAPC chair can assign a small sub-panel to approve qualifying studies — cutting months off the typical timeline.

• • Confidentiality protection: Extends authority for closed-session meetings to protect trade secrets and proprietary data until 2028.

• • Due process: RAPC may revoke approval for reasonable cause and after notice and opportunity to correct issues.

• • Sunset: Streamlined review authority ends January 1, 2028, unless renewed by the Legislature.

Why It Matters:

AB 1103 signals California’s commitment to advancing psychedelic research and treatment for mental health issues by eliminating roadblocks to approving the study of psychedelics. While other legislators in other states such as Oregon, Colorado and New Mexico have created a legal regulated market, will this contribute to pathway for California?

Expect new movement in this space over the next year or two. As things evolve, advisors, clinicians, and others interested in these developments should feel free to connect.